OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
22180055

ZGOO Holdings Co Ltd

Healthcare Facilities & ServicesVerified

ZGOO Holdings has a strong liquidity position, as evidenced by a current ratio of 6.39, indicating that the company holds significantly more current assets than current liabilities. However, the company's liquidity is rated as medium due to a negative net cash position after subtracting total debt. The company's debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal reliance on debt financing. Profitability metrics for ZGOO Holdings are negative, with a return on equity of -3.88% and a return on assets of -3.13%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company reported a net loss of KRW 1,642,048,770 and an operating loss of KRW 2,394,889,610 in the latest financial period. ZGOO Holdings does not disclose specific revenue segments or geographic breakdowns in the provided data, making it difficult to assess the concentration of its revenue sources or geographic exposure. The absence of detailed segment data limits the ability to evaluate the company's diversification and potential vulnerabilities to regional or product-specific risks. The company's growth trajectory is uncertain, as the provided data does not include forward-looking revenue projections or historical growth rates. The operating cash flow is negative at KRW -1,562,284,350, and the free cash flow is also negative at KRW -1,008,556,250, indicating that the company is not generating sufficient cash from operations to fund its activities or growth initiatives. ZGOO Holdings faces a medium liquidity risk due to its negative net cash position after subtracting total debt. The company's dilution risk is rated as low, with no significant dilution potential identified in the basic shares outstanding. The company has not made any adjustments to its valuations that would suggest imminent dilution or capital raising activities. There are no recent events or filings provided in the data that would indicate significant changes in the company's operations, strategy, or financial position. The absence of recent transcripts or filings suggests that the company may not be actively communicating with investors or disclosing material developments.

30-day price · 221800-8150.00 (-39.5%)
Low$11950.00High$24000.00Close$12500.00As of18 May, 00:00 UTC
Profile
CompanyZGOO Holdings Co Ltd
Ticker221800.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. ZGOO Holdings Co Ltd operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment.

Classification. ZGOO Holdings is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

ZGOO Holdings has a strong liquidity position, as evidenced by a current ratio of 6.39, indicating that the company holds significantly more current assets than current liabilities. However, the company's liquidity is rated as medium due to a negative net cash position after subtracting total debt. The company's debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal reliance on debt financing. Profitability metrics for ZGOO Holdings are negative, with a return on equity of -3.88% and a return on assets of -3.13%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The company reported a net loss of KRW 1,642,048,770 and an operating loss of KRW 2,394,889,610 in the latest financial period. ZGOO Holdings does not disclose specific revenue segments or geographic breakdowns in the provided data, making it difficult to assess the concentration of its revenue sources or geographic exposure. The absence of detailed segment data limits the ability to evaluate the company's diversification and potential vulnerabilities to regional or product-specific risks. The company's growth trajectory is uncertain, as the provided data does not include forward-looking revenue projections or historical growth rates. The operating cash flow is negative at KRW -1,562,284,350, and the free cash flow is also negative at KRW -1,008,556,250, indicating that the company is not generating sufficient cash from operations to fund its activities or growth initiatives. ZGOO Holdings faces a medium liquidity risk due to its negative net cash position after subtracting total debt. The company's dilution risk is rated as low, with no significant dilution potential identified in the basic shares outstanding. The company has not made any adjustments to its valuations that would suggest imminent dilution or capital raising activities. There are no recent events or filings provided in the data that would indicate significant changes in the company's operations, strategy, or financial position. The absence of recent transcripts or filings suggests that the company may not be actively communicating with investors or disclosing material developments.
Key takeaways
  • ZGOO Holdings has a strong current ratio but faces medium liquidity risk due to a negative net cash position.
  • The company is not profitable, with negative returns on equity and assets.
  • The capital structure is conservative, with minimal debt and a low debt-to-equity ratio.
  • Growth trajectory is unclear due to the absence of forward-looking revenue projections.
  • The company's risk profile is characterized by medium liquidity risk and low dilution risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$25.59B
Gross profit$5.39B
Operating income-$2.39B
Net income-$1.64B
R&D
SG&A
D&A
SBC
Operating cash flow-$1.56B
CapEx-$201.4M
Free cash flow-$1.01B
Total assets$52.51B
Total liabilities$10.21B
Total equity$42.30B
Cash & equivalents
Long-term debt$442.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$25.59B-$2.39B-$1.64B-$1.01B
FY-1$25.04B-$3.11B-$2.84B-$2.66B
FY-2$30.79B-$1.38B$645.9M-$675.9M
FY-3$69.01B$15.69B$13.16B$12.15B
FY-4$50.55B$9.03B$9.24B$9.42B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$52.51B$42.30B
FY-1$44.98B$34.43B
FY-2$49.20B$37.99B
FY-3$51.03B$33.84B$1.43B
FY-4$41.33B$21.52B$16.48B
PeriodOCFCapExFCFSBC
FY0-$1.56B-$201.4M-$1.01B
FY-1-$1.73B-$353.5M-$2.66B
FY-2-$2.55B-$977.9M-$675.9M
FY-3$24.41B-$1.14B$12.15B
FY-4$12.75B-$387.4M$9.42B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$6.27B-$928.1M-$678.9M-$603.3M
FQ-1$6.87B-$583.0M-$746.0M-$554.7M
FQ-2$6.83B-$196.8M$31.4M$212.5M
FQ-3$5.62B-$687.0M-$248.5M-$63.0M
FQ-4$6.26B-$1.15B-$2.02B-$1.83B
FQ-5$6.43B-$833.4M-$449.6M-$295.5M
FQ-6$6.76B-$449.6M-$25.7M$84.8M
FQ-7$5.58B-$676.8M-$342.6M-$276.8M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$52.51B$42.30B
FQ-1$44.54B$33.59B
FQ-2$44.71B$34.29B
FQ-3$44.34B$34.10B
FQ-4$44.98B$34.43B
FQ-5$47.25B$36.61B$17.96B
FQ-6$47.07B$37.13B
FQ-7$47.20B$37.27B
PeriodOCFCapExFCFSBC
FQ0-$1.56B-$201.4M-$603.3M
FQ-1-$252.3M-$64.5M-$554.7M
FQ-2-$71.6M-$49.4M$212.5M
FQ-3$373.6M-$24.5M-$63.0M
FQ-4-$1.73B-$353.5M-$1.83B
FQ-5-$1.35B-$335.5M-$295.5M
FQ-6-$1.57B-$275.5M$84.8M
FQ-7-$691.0M-$163.2M-$276.8M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$42.30B
Net cash-$442.6M
Current ratio6.4
Debt/Equity0.0
ROA-3.1%
ROE-3.9%
Cash conversion95.0%
CapEx/Revenue-0.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric221800Activity
Op margin-9.4%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin-6.4%8.6% medp25 6.3% · p75 12.4%bottom quartile
Gross margin21.1%28.8% medp25 28.8% · p75 28.8%bottom quartile
CapEx / revenue-0.8%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity1.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-19 00:25 UTCJob: 658dfe8f